Remimazolam matches propofol on recovery quality after meniscectomy
A randomized trial in adults undergoing elective arthroscopic meniscectomy found no significant difference in quality of recovery on postoperative day 1 between remimazolam-based and propofol-based total intravenous anesthesia. Global QoR-40 scores were numerically similar, with no statistically meaningful separation between groups, even though the two drugs behaved differently in the operating room and in the recovery unit.
The result is clinically relevant because meniscectomy is usually a short, fast-turnover procedure in which patients are expected to mobilize early and leave the hospital within a day. In that setting, the anesthesia plan is judged not only by blood pressure or wake-up time, but by how a patient feels once the immediate haze of surgery has passed. The QoR-40 captures that broader experience across physical comfort, independence, emotional state, psychological support, and pain.
The study enrolled 80 adults, and 71 completed the postoperative QoR-40 assessment: 36 in the propofol arm and 35 in the remimazolam arm. Baseline characteristics were not presented in the excerpted abstract, but the final analysis was built around a single center, a single operation type, and a tightly controlled anesthetic protocol. That design gives the findings a focused bedside relevance for ambulatory orthopedic anesthesia.
Hemodynamic stability came with slower emergence
The sharpest physiological contrast appeared during the case itself. Intraoperative hypotension requiring ephedrine occurred more often with propofol than with remimazolam, 44.4% versus 17.1%. For anesthesiologists, that difference matters because propofol’s vasodilatory and myocardial-depressant effects can lower arterial pressure quickly, especially in patients receiving concurrent opioid infusions. Remimazolam, a benzodiazepine anesthetic with rapid metabolism, may preserve circulatory stability more effectively during induction and maintenance, which aligns with the lower vasopressor requirement seen here.
A slower wake-up followed that stability. Time to full alertness was longer with remimazolam, 37 minutes versus 18 minutes with propofol, and post-anesthesia care unit stay was also longer, 38 minutes versus 30 minutes. Those delays are not trivial in short-stay surgery, where readiness for discharge depends on alertness, mobility, oral intake, and comfort. The pharmacology explains the trade-off: the same sedative profile that may buffer hemodynamic swings can extend recovery room observation before a patient reaches discharge-ready consciousness.
The bedside consequence is immediate. If a clinician prioritizes blood pressure stability, remimazolam has an advantage; if the priority is rapid emergence and throughput, propofol remains hard to beat.
Patient-reported recovery did not separate on the main endpoint
The primary endpoint, global QoR-40 score on postoperative day 1, did not differ significantly. Scores were 166.1 ± 16.8 with propofol and 170.6 ± 13.6 with remimazolam, with a mean difference of −4.5 and a 95% confidence interval crossing zero. In practical terms, the overall patient-perceived recovery experience one day after surgery looked similar under both anesthetic strategies.
An exploratory domain analysis found one signal: the emotional-state domain favored remimazolam, with scores of 39.2 ± 2.5 versus 37.0 ± 4.3. Because this was exploratory, it should be interpreted cautiously, yet the pattern is biologically plausible. Benzodiazepine-based anesthesia may blunt perioperative distress, and smoother hemodynamics can reduce the sympathetic and subjective stress burden that patients feel in the hours after surgery. Still, the trial does not establish a durable psychological benefit, and the main composite endpoint did not move.
Pain and rescue analgesic pathways were built into the protocol, including acetaminophen for all patients and rescue opioids for higher verbal numerical rating scores. Postoperative nausea and vomiting were assessed as well, but the excerpt does not provide comparative results for that outcome. Without those data, the recovery profile cannot be reduced to a single comfort measure.
What this trial means for short orthopedic anesthesia
This trial sits in a practical zone of anesthesia choice rather than a high-drama efficacy contest. For arthroscopic meniscectomy, where discharge often follows quickly and patients care about waking up comfortably, the anesthetic choice influences more than intraoperative monitoring. It shapes how much vasopressor support is needed, how soon a patient is fully alert, and how long the PACU bed stays occupied.
The study also reinforces a familiar perioperative pattern: physiologic stability and speed of emergence do not always move in the same direction. Remimazolam’s profile here suggests a calmer circulatory course, while propofol preserved quicker recovery of alertness. Neither agent clearly improved the overall patient-reported recovery score at 24 hours, so the choice may come down to whether the team values hemodynamic resilience or faster discharge readiness more highly in a given patient.
Several guardrails remain important. This was a single-center trial, and only 71 patients were included in the final analysis. The study was also confined to one surgery type, one age spectrum, and one postoperative pathway, so the findings cannot simply be transferred to more painful orthopedic procedures or to patients with greater cardiopulmonary fragility. The attending anesthesiologists were not blinded, which is difficult to avoid when the infusion methods differ, although outcome assessment remained blinded.
The most useful message is narrow and concrete: in elective arthroscopic meniscectomy, remimazolam did not improve the main patient-reported recovery score compared with propofol, but it did reduce intraoperative hypotension at the cost of slower full alertness. Future work will need to test whether that same balance holds in larger orthopedic cohorts, in outpatient pathways with tighter turnover targets, and in patients where hypotension carries a higher clinical price.